Synaptogenix Inc (SNPX)

[runncoach]

I'm not sure how it plays out near term. Plenty of money for the open label extension and to start Fragile X study. Company will get and analyze more data before figuring out how to set up the dosing study and at some point figure out how to approach P3, whether with a partner or not. There's no rush to raise funds until all has been presented. If we get even better numbers at other data points other than week 12, it will be even further validation of bryostatin's response in humans. Those phase 2a results were pretty detailed. Really hoping we get similar individual detail to the 2b in the next month or two. I don't see how anyone can not be impressed with the 3 CU patient results.
It's just a waiting game now.